

The Kyrgyzstan Republic

Support for Vaccine: Pneumococcal

This Decision Letter sets out the Programme Terms of a Programme.

1. Country:	Kyrgyz Rep																		
2. Vaccine grant number:	15-KGZ-08c-Y, 1516-KGZ-12c-X, 17-KGZ-12c-X, 1821-KGZ-12c-X																		
3. Date of Decision Letter:	30-Sep-2019																		
4. Date of the Partnership Framework Agreement:	May 16, 2014																		
5. Programme title:	New Vaccine Support (NVS), Pneumococcal , Routine																		
6. Vaccine type:	Pneumococcal																		
7. Requested product presentation and formulation of vaccine:	PCV13, 1 dose per vial LIQUID																		
8. Programme Duration:¹	2015-2021																		
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement)																		
	2015-2019	2020	2021	Total²															
Programme Budget (US\$)	6,258,424	1,062,000	1,239,500	8,559,924															
10. Vaccine introduction grant	<table border="1"> <thead> <tr> <th colspan="3">Approval</th> </tr> <tr> <th>Year</th> <th>Grant Number</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>2015</td> <td>15-KGZ-08c-Y</td> <td>122,500</td> </tr> </tbody> </table> <table border="1"> <thead> <tr> <th colspan="2">Disbursement</th> </tr> <tr> <th>Disbursement date</th> <th>Amount (US\$)</th> </tr> </thead> <tbody> <tr> <td>16 January, 2015</td> <td>122,500</td> </tr> </tbody> </table>				Approval			Year	Grant Number	Amount (US\$)	2015	15-KGZ-08c-Y	122,500	Disbursement		Disbursement date	Amount (US\$)	16 January, 2015	122,500
Approval																			
Year	Grant Number	Amount (US\$)																	
2015	15-KGZ-08c-Y	122,500																	
Disbursement																			
Disbursement date	Amount (US\$)																		
16 January, 2015	122,500																		
11. Product switch grant:	Not applicable																		
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement)																		
	2015-2019	2020																	
Type of supplies to be purchased with Gavi funds																			
Number of vaccine doses		287,100																	
Annual Amounts (US\$)	6,258,424	1,062,000																	
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.																		

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

14. Self-procurement:	Not applicable							
15. Co-financing obligations:	According to the co-financing policy, the Country falls within the group: Preparatory transition phase							
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.								
Type of supplies to be purchased with Country funds in each year	2020	2021						
Number of vaccine doses	73,400	111,100						
Number of AD syringes	76,800	116,400						
Number of re-constitution syringes	-	-						
Number of safety boxes	850	1,300						
Value of vaccine doses (US\$)	241,917	366,417						
Total co-financing payments (US\$) (including freight)	253,500	384,000						
16. Operational support for campaigns:	Not applicable							
17. Additional Reporting Requirements:	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;"></th> <th style="width: 30%;">Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td style="vertical-align: top;"> 31 March 2020 15 May 2020 </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td style="vertical-align: top;">To be agreed with Gavi Secretariat</td> </tr> </tbody> </table>			Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat
	Due dates							
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	31 March 2020 15 May 2020							
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat							
18. Financial clarifications:	Not applicable							
19. Other conditions:	Not applicable							

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30-Sep-2019